Samuel M. Cohen, M.D., Ph.D.

Department Affiliations
Professor
Havlik-Wall Professor of Oncology (1985)

Interests
Chemical Carcinogenesis, Toxicology and Risk Assessment, Surgical Pathology, Urologic Pathology
For full details of Dr. Cohen's research, please visit his lab's webpage.

Education and Training
B.S. (Honors) University of Wisconsin, 1967
M.D., Ph.D. (Experimental Oncology) University of Wisconsin, 1972
Residency, St. Vincent Hospital, Worcester, MA, 1972-1975
Board Certified in Anatomic and Clinical Pathology, 1976

Teaching Activities
Medical Students: Small group discussions and laboratories
Graduate students: Advisor, supervisory committees
Residents: Surgical pathology, conferences

National Activities
Editorial Board or Associate Editor:
Fd. Chem. Toxicol., Toxicol. Pathol. Crit. Rev. Toxicol., Toxicoogy, Reg. Toxicol. Pharmicol, Int. J. Oncology, Urologic Oncology, Toxicol. Pathol., Pathol. Intl., Crit. Rev. Toxicol., Toxicology, J. Toxicol.
Advisory Panels:
Int. Life Sci. Inst. (ILSI) - Health and Environmental Sciences Institute Board of Trustees (HESI), 2001-present; Chairman, 2006-2008
International Life Sciences Institute Board of Trustees, 2007- 2016, Vice Chairman, 2010-2012. Chairman, 2012-2015
WHO-IPCS; Expert Panel on Carcinogens, 1999-2006
Expert Panel of the Flavors and Extracts Manufacturers Association, 2002-present
Numerous committees & panels with NIH, EPA, FDA, WHO, IARC, IPCS, national and international scientific organizations.
Academy of Toxicological Sciences, fellow 1995-present (Board of Directors 2014-present)

Notable Publications
Yamada, T., Cohen, S.M., and Lake, B.G. The mode of action for phenobarbital-induced rodent liver tumor formation is not relevant for humans: recent studies with humanized mice. Toxicol. Sci., 147:298-299, 2015.

Wood, C.E., Hukkanen, R.R., Sura, R., Boyce, R., Jacobson-Kram, D., Nolte, T., Odin, M., and Cohen, S.M. Scientific and regulatory policy committee (SRPC) review: Interpretation and use of cell proliferation data in cancer risk assessment. Toxicol. Pathol., 43:760-775, 2015.

Embry, M.R., Bachman, A., Bell, D., Boobis, A., Cohen, S.M., Dellarco, M., Dewhurst, I., Doerrer, N., Hines, R., Moretto, A., Pastoor, T., Phillips, R., Rowlands, J.C., Tanir, J.Y., Wolf, D., and Doe, J. Risk assessment in the 21st century (Risk21): Roadmap and matrix. Crit. Rev. Toxicol., 44(S3): 6-16, 2014.

Simon, T., Simons, Jr., S.S., Preston, R.J., Boobis, A.R., Cohen, S.M., Doerrer, N.G., Fenner-Crisp, P.A., McMullin, T., McQueen, C.A., and Rowlands, J.C.  The use of mode of action information in risk assessment: quantitative key events/dose-response framework (Q-KEDRF) for modeling the dose-response for key events. Crit. Rev. Toxicol., 44(S3): 17-43, 2014.

DaRocha, M.S., Arnold, L.L., De Oliveira, M.L.C.S., Ihlasch, S.M., Cardoso, A.P.F., Pontes, M.G.N., Dodmane, P.R., Cohen, S.M., and de Camargo, J.L.V. Diuron-induced rat urinary bladder carcinogenesis: mode of action and human relevance evaluation using the International Programme on Chemical Safety framework. Crit. Rev. Toxicol., 44: 393-406, 2014.

Dodmane, P.R., Arnold, L.L., Muirhead, D. E., Suzuki, S., Yokohira, M., Pennington, K.L., Lu, X., Le, X.C., and Cohen, S.M. Characterization of intracellular inclusions in the urothelium of mice exposed to inorganic arsenic. Toxicol. Sci., 137:36-46, 2014.

Liu, L., Kakiuchi-Kiyota, S., Arnold, L.L., Johansson, S.L., Wert, D., and Cohen, S.M. Pathogenesis of human hemangiosarcomas and hemangiomas. Human Pathol., 44:2302-2311, 2013.

Kakiuchi-Kiyota, S., Crabbs, T.A., Arnold, L.L., Pennington, K.L., Cook, J.C., Malarkey, D.E., and Cohen, S.M. Evaluation of expression profiles of hematopoietic stem cell, endothelial cell, and myeloid cell antigens in spontaneous and chemically induced hemangiosarcomas and hemangiomas in mice. Toxicol. Pathol., 41:709-721, 2013.

Wedel, W.R., Muirhead, D.E., Arnold, L.L., Dodmane, P., Maness-Harris, L., Hoyt, R., and Cohen, S.M. Urothelial cell intracytoplasmic inclusions after treatment of promyelocytic leukemia with arsenic trioxide. Toxicol. Sci., 134:271-275, 2013.

Hard, G., Banton, M.I., Bretzlaff, R.S., Dekant, W., Fowles, J., Mallett, A.K., McGregor, D., Roberts, K.M., Sielken, R.L., Valdez-Flores, C., and Cohen, S.M. Consideration of rat chronic progressive nephropathy (CPN) in regulatory evaluations for carcinogenicity. Toxicol. Sci., 132:268-275, 2013

For a detailed list of publications, click here.